Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novozymes to acquire Philom Bios
This represents a total equity value of approximately CAD25.6 million, corresponding to an enterprise value-to-sales multiple of approximately 2.0, based on 2005/06 sales. The offer includes outstanding stock
This represents a total equity value of approximately CAD25.6 million, corresponding to an enterprise value-to-sales multiple of approximately 2.0, based on 2005/06 sales. The offer includes outstanding stock
Pfizer Ireland has agreed to invest $1.5 million in cash to acquire 2,516,299 new Entelos shares, representing 3.3% of the enlarged share capital of Entelos. Following the subscription,
The study is designed for the evaluation of the safety and tolerability of the SMaRT replacement strain, A2JM, in healthy, adult male subjects, and includes an institutionalized phase
Lanzhou Roya is a bovine serum manufacturer in China. Bovine serum is used in production of many vaccines as well as for laboratory scientific research. Dr Liang Qiao,
VR040 is Ventura’s proprietary formulation of apomorphine, delivered to the bloodstream by oral inhalation through the lungs using the company’s proprietary dry powder inhalation (DPI) technology. Presented study
Zytopic Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, such as atopic dermatitis. Clere is a hypoallergenic (no perfumes or dyes)
This study is designed to evaluate safety and preliminary efficacy of topical psoriasis drug, PTH (1-34). Approximately 54 subjects will be enrolled and randomized to receive one of
The FDA will now have sixty days in which to consider the new drug application (NDA) for filing. If accepted for filing, the FDA will have an additional
In addition to the $35 million total up-front payment, NPS has the potential to earn up to $150 million in payments related to the attainment of certain regulatory
The Phase II study enrolled seven patients with locally advanced rectal cancer. TNFerade was administered weekly to patients via intratumoral injections during the first five weeks of radiotherapy.